Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database  by Dworkin, R.H. et al.
Osteoarthritis and Cartilage 19 (2011) 483e492Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness
to treatment effects in the REPORT database
R.H. Dworkin y*, S. Peirce-Sandner y, D.C. Turk z, M.P. McDermott x, A. Gibofsky k,
L.S. Simon{, J.T. Farrar#, N.P. Katz yyzz
yDepartment of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
zDepartment of Anesthesiology, University of Washington, Seattle, WA, USA
xDepartment of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
kDivision of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA
{ SDG, LLC, Cambridge, MA, USA
#Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, PA, USA
yyAnalgesic Solutions, Natick, MA, USA
zz Tufts University, Boston, MA, USAa r t i c l e i n f o
Article history:
Received 24 December 2010
Accepted 14 February 2011
Keywords:
Outcome measures
Randomized clinical trials
Osteoarthritis
Responsiveness
Treatment effect
Standardized effect size* Address correspondence and reprint requests to: R
Rochester, NY 14642, USA. Tel: 1-585-275-8214; Fax:
E-mail address: robert_dworkin@urmc.rochester.e
1063-4584/$ e see front matter  2011 Osteoarthriti
doi:10.1016/j.joca.2011.02.020s u m m a r y
Introduction: Treatment response in randomized clinical trials (RCT) of osteoarthritis (OA) has been assessed
bymultiple primary and secondary outcomes, including pain, function, patient and clinician global measures
of status and response to treatment, and various composite and responder measures. Identifying outcome
measures with greater responsiveness to treatment is important to increase the assay sensitivity of RCTs.
Objective: To assess and compare the responsiveness of different outcome measures used in placebo-
controlled RCTs of OA.
Search strategy: The Resource for Evaluating Procedures and Outcomes of Randomized Trials database
includes placebo-controlled clinical trials of pharmacologic treatments (oral, topical, or transdermal) for
OA identiﬁed from a systematic literature search of RCTs published or publicly available before August 5,
2009, which was conducted using PubMed, the Cochrane collaboration, publicly-available websites, and
reference lists of retrieved publications.
Data collection and analysis: Data collected included: (1) pain assessed with single-item ratings and the
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale; (2) patient and
clinician global measures of status, improvement, and treatment response; (3) function assessed by the
WOMACfunction subscale; (4) stiffness assessedby theWOMACstiffness subscale; and (5) theWOMACand
LequesneAlgofunctional Indexcompositeoutcomes.Measuresweregroupedaccording to the total number
of response categories (i.e., <10 categories or 10 categories). The treatment effect (difference in mean
change frombaseline between theplacebo andactive therapyarms) and standardized effect size (SES)were
estimated for each measure in a meta-analysis using a random effects model.
Results: There were 125 RCTs with data to compute the treatment effect for at least one measure; the
majority evaluated non-steroidal anti-inﬂammatory drugs (NSAIDs), followed by opioids, glucosamine
and/or chondroitin, and acetaminophen. In general, the patient-reported pain outcome measures had
comparable responsiveness to treatment as shown by the estimates of treatment effects and SES.
Treatment effects and SESs were generally higher for patient-reported global measures compared with
clinician-rated global measures but generally similar for the WOMAC and Lequesne composite measures.
Conclusions: Comparing different outcome measures using meta-analysis and selecting those that have
the greatest ability to identify efﬁcacious treatments may increase the efﬁciency of clinical trials of
treatments for OA. Improvements in the quality of the reporting of clinical trial results are needed to
facilitate meta-analyses to evaluate the responsiveness of outcome measures and to also address other
issues related to assay sensitivity.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.obert H. Dworkin, Department of Anesthesiology, University of Rochester Medical Center, 601 Elmwood Ave., Box 604,
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able before August 5, 2009, which was conducted using PubMed,An appreciable percentage of patients with osteoarthritis (OA)
are refractory to existing analgesic treatments, and the patients
who do respond to these treatments often obtain only partial relief
of their pain1,2. Considerable effort is therefore being devoted to the
development of new treatments for OA and to conducting
randomized clinical trials (RCTs) to evaluate their efﬁcacy and
safety. In designing these trials, it is critically important that
methodological factors are identiﬁed that might improve their
assay sensitivity, which has been deﬁned as “the ability to distin-
guish an effective treatment from a less effective or ineffective
treatment”3. Assuming that the treatment studied is efﬁcacious,
RCTs with greater assay sensitivity are less likely to have falsely
negative study results and can detect treatment effects with
smaller sample sizes. This not only hastens the time to study
completion and reduces costs, but also exposes fewer subjects to
the unknown risks of novel treatments.
An essential aspect of the assay sensitivity of a clinical trial
involves the responsiveness to treatment of its outcome measures.
The importance of assay sensitivity in identifying efﬁcacious
treatments as efﬁciently as possible provides a compelling rationale
for identifying and then selecting measures that have the greatest
responsiveness (assuming other characteristics of the measures do
not offset this, for example, lack of clinical importance or
substantially increased patient burden).
Response to treatment in RCTs of patients with OA has been
measured by patient-reported assessments of pain, function, and
stiffness as well as by patient and clinician global evaluations of
disease status and response to treatment4e6. Various visual analog
scales (VAS) and numeric rating scales (NRS) as well as disease-
speciﬁc outcome measures, such as the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC)7 and the
Lequesne Algofunctional Index8, have been widely used as primary
and secondary outcome measures in OA trials. To encourage stan-
dardization among the diverse measures that are available, the
Osteoarthritis Research Society International (OARSI) and Outcome
Measures in Rheumatology (OMERACT) have recommended core
outcome domains and measures for OA clinical trials9e12. For RCTs
of chronic pain conditions in general, the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
has recommended consideration of speciﬁc outcome domains13,
measures14, approaches to developing new measures15, and strat-
egies for evaluating the clinical importance of treatment
outcomes16,17.
IMMPACT has also created the Resource for Evaluating Proce-
dures and Outcomes of Randomized Trials (REPORT) to examine
relationships between clinical trial research methods and study
outcomes and thereby contribute to the development of an
evidence-based approach to analgesic clinical trial design18,19.
REPORT consists of comprehensive databases of RCTs of acute and
chronic pain conditions (e.g., neuropathic pain, ﬁbromyalgia,
chronic low back pain, and acute post-operative pain), which are at
present limited to trials of pharmacologic treatments. In this article,
we evaluate and compare the responsiveness to treatment of
commonly used outcome measures in placebo-controlled RCTs of
pharmacologic treatments in the REPORT database of OA trials.Materials and methods
Literature search
The REPORT database of OA clinical trials includes placebo-
controlled trials of pharmacologic treatments identiﬁed fromCochrane collaboration systematic reviews, publicly-available
websites, and references from published reports of trials that met
inclusion criteria, and other retrieved publications20. The search
terms included “osteoarthritis”, “degenerative joint disease”,
“coxarthrosis”, and “gonarthrosis,” with limits of “Randomized
Controlled Trial”, “Human”, and “English” applied. Only trials that
met the following criteria were included: (1) results reported in
publicly-available sources, including publications and websites
(e.g., www.clinicaltrialresults.org); (2) evaluated oral, topical, or
transdermal pharmacologic treatments; (3) had treatment dura-
tions of at least 7 days; (4) used a parallel group design; (5)
included patients with OA of the knee or hip; and (6) were placebo-
controlled and double blinded (except for one single blind trial).
Clinical trials reported only in abstract form were not included.
Information was extracted on standard forms and entered into
a spreadsheet. Variables collected from each trial that were used in
the present analyses included the following, when available: (1)
eligibility criteria, including joint(s) studied; (2) active treatments;
(3) baseline and endpoint mean values and either the respective
standard deviation (SD) or information fromwhich this SD could be
derived (e.g., standard error, conﬁdence interval); (4) speciﬁc
outcome measures and scales used for all primary and secondary
endpoints related to pain, function, stiffness, and patient and
clinician global assessments of status, improvement, and treatment
response; and (5) responder outcomes based on pain reduction,
patient and clinician global or treatment response assessments, and
OMERACTeOARSI responder criteria5,11. The statistical signiﬁcance
for the comparison of each active treatment groupwith the placebo
group was recorded for all primary and secondary endpoints.
Study outcomes
Data from primary and secondary endpoints using 0e10 NRS,
0e10 cm VAS, and other measures were transformed to a 0e100
scale21. Although NRSs and VASs may have somewhat different
psychometric properties, responses to these two types of measures
of pain intensity are highly correlated and there is no evidence that
their responsiveness to change and to treatment effects differs14.
The placebo group and treatment group mean changes from
baseline and standardized effect sizes (SESs) were determined as
follows:
1. Placebo group mean change from baseline, as reported or
computed as the difference in mean responses at the baseline
and ﬁnal visits.
2. Active treatment group mean change from baseline, as repor-
ted or computed as the difference in mean responses at the
baseline and ﬁnal visits.
3. Treatment effect: active treatment group mean change from
baseline e placebo group mean change from baseline.
4. Pooled SD:
ðNTreatment  1Þ  ðSDTreatmentÞ2þðNPlacebo  1Þ  ðSDPlaceboÞ2
NTreatment þNPlacebo  2
5. SES: treatment effect/pooled SD
When only ﬁnal visit means were available (i.e., no mean
baseline or change from baseline values were present), expressed
as either actual mean values or mean values adjusted for baseline,
the treatment effect was calculated by subtracting the placebo
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value. The SES was calculated only for trials that reported the cor-
responding measure of variability (e.g., SD) of the change from
baseline22 or of the ﬁnal values adjusted for baseline.
Analyses focused on RCTs of efﬁcacious treatments, which were
considered those medications that are “recommended treatments”
for OA in prominent national and international guidelines23,24.
Given the difﬁculty of establishing which other treatments truly
lack efﬁcacy, supplementary analyses are presented in Appendix I
for RCTs examining all treatments irrespective of whether they
are recommended or not. For trials with multiple arms examining
the same treatment (e.g., different dosages or titration schedules),
a mean value for each treatment was calculated by computing the
average response, weighted according to sample size, across all
arms of the same treatment within a trial so that each active
treatment contributed only one value per trial for each outcome
measure.
The outcome measures were included in the analyses of treat-
ment effects and SESs if there were at least ﬁve RCTs with sufﬁcient
data25. Pain-related outcome measures included: (1) “pain”,
representing spontaneous pain, pain at rest, or otherwise undes-
ignated pain; (2) “active pain”, representing pain during a weight-
bearing activity, for example, when walking or standing, but not in
response to passive movement by an examiner or clinician; (3) the
WOMAC pain subscale7; and (4) item one of the WOMAC pain
subscale (pain walking on a ﬂat surface)7. Patient and clinician
measures were based on global assessments (e.g., of OA status or
overall improvement) and on response to treatment of OA. Function
and stiffness endpoints were measured by the WOMAC function
and stiffness subscales7, and composite outcomes were represented
by the WOMAC total score7 and the Lequesne Algofunctional
Index8,26, a 10-item composite measure of pain, stiffness, walking
distance, and other aspects of function. All of these measures were
also evaluated according to the number of response categories for
ratings made by the patient or clinician during the trial, speciﬁcally
(1) scales with 10 response categories or more (e.g., NRS with
a 0e10 scale or VAS with a 0e100 mm scale); and (2) scales with
fewer than 10 response categories (e.g., Likert scale with a 0e3
verbal rating scale). Formeasures that consist of multiple individual
rating scales each having fewer than 10 response categories, the
number of response categories was considered the total number of
possible categories; for example, a measure composed of four 0e3
Likert scales with a maximum total score of 12 was considered
a scale with 10 response categories. Responder outcomes were
classiﬁed according to the instrument used to categorize
responders and non-responders, speciﬁcally, pain (i.e., 30%
reduction), patient and clinician global ratings and treatment
response assessments, and OMERACTeOARSI responder criteria5,11,
which are based on absolute and percentage improvements in pain,
function and patient global assessments.
Statistical analyses
Due to the expected heterogeneity among the different studies
(including eligibility criteria, intervention studied, evaluation
protocol, concomitant treatments, and other factors), overall esti-
mates of treatment effects and SESs for each outcome measure
were obtained from random effects models that treated study as
a random effect27,28. These overall estimates were computed as
weighted averages of the individual study estimates, with the
weights being inversely proportional to the estimated variances of
the individual study estimates27,28. Responder measures with
binary outcomes (i.e., responder vs non-responder, however
deﬁned) were evaluated in the same manner, with the overall
percentage of responders estimated by the weighted average of thestudy-speciﬁc estimated percentages, with the weights being
inversely proportional to the estimated variances of the individual
study estimates27,28.
The number of response categories used by outcome measures
could be associated with differences in either treatment effects or
SESs, for example, fewer response categories could be associated
with less responsiveness to change. To evaluate this possibility,
mixed effects models with number of scale categories as a ﬁxed
effect (0¼ scales with <10 response categories, 1¼ scales with 10
response categories) and study as a random effect was used.
Because the effect of number of scale response categories was
signiﬁcant for clinician global status for treatment effect and SES
and showed trends for the other measures that used both of these
two groups of number of response categories, treatment effects and
SESs were summarized overall as well as according to number of
scale categories when an outcome measure had adequate data for
both groups of number of response categories.
The estimates of treatment effect and SES for selected
measures were compared using a mixed effects model with
study as a random effect and the measure of interest as a ﬁxed
effect. The measures selected for comparison were the most
commonly used outcome measures that were similar with
respect to the underlying construct being assessed (i.e., pain,
global status, overall composite outcome): (1) spontaneous pain
vs WOMAC pain; (2) patient vs clinician global assessment; and
(3) WOMAC total score vs Lequesne index. In the comparisons of
these selected measures, when there were studies that had
values for both of the measures, the measure with the greatest
number of values in each of the analyses was discarded from the
study to preserve independence. For the random effects models,
when a trial included two or more different active treatments,
only one active treatment arm per placebo group was retained in
order to preserve independence. A single active treatment arm
was randomly selected from trials with two or more different
active treatments and any other active treatment arms were
discarded.
For each outcomemeasure, the following data are presented: (1)
estimates from the random effects models overall and for each of
the two groups of measures differing in number of response cate-
gories, when data from ﬁve or more trials were available25; (2)
overall unweighted means across all arms to show treatment
effects and SESs for the greatest number of treatment arms,
including those for which no measure of variability was available.
The numbers of treatment arms available for the random effects
models are lower than the number of arms used in calculating the
unweighted means because only one active arm per trial was used
and the random effects model requires an estimate of variance that
was not always available. The sample sizes for estimates of the SESs
are often lower than for the treatment effects because SES was
computed only for studies that reported variance adjusted for
baseline values22. In comparing selected measures (e.g., sponta-
neous pain and WOMAC pain) for treatment effects and for SESs,
the sample size is further reduced because one measure was
dropped from studies that reported both measures in order to
preserve independence. In the following presentation and discus-
sion of the results, we focus on estimates from the random effects
models.
Results
A total of 1774 articles were retrieved from the PubMed search,
Cochrane collaboration reviews related to pharmacotherapy for OA,
and the clinicaltrialresults.org website, from which 167 blinded,
randomized, and placebo-controlled trials of oral, topical, and
transdermal therapies for OA of the knee and/or hip were
Table I
Active treatment groups according to outcome measure and treatment type for trials with a non-missing value for treatment vs placebo difference or responder outcome
Measure Total number of
active treatment
groups
Non-steroidal
anti-inﬂammatory
drug, N (%)*
Acetaminophen
(paracetamol),
N (%)
Glucosamine/chondroitiny,
N (%)
Opioid analgesicz, N (%) Other,
N (%)
Pain 83 45 (54.2) 0 (0) 11 (13.3) 11 (13.3) 16 (19.3)
Pain (with activity) 30 24 (80.0) 1 (3.3) 2 (6.7) 1 (3.3) 2 (6.7)
WOMAC pain subscale 99 63 (63.6) 3 (3.0) 4 (4.0) 11 (11.1) 18 (18.2)
WOMAC pain walkingx 21 19 (90.5) 0 (0) 0 (0) 2 (9.5) 0 (0)
Patient global rating 66 53 (80.3) 1 (1.5) 3 (4.5) 4 (6.1) 5 (7.6)
Patient response to therapy 20 17 (85.0) 0 (0) 2 (10.0) 1 (5.0) 0 (0)
Clinician global rating 50 44 (88.0) 0 (0) 2 (4.0) 2 (4.0) 2 (4.0)
Clinician response to therapy 11 10 (90.9) 0 (0) 0 (0) 1 (9.1) 0 (0)
Lequesne algofunctional index 32 16 (50.0) 1 (3.1) 7 (21.9) 0 (0) 8 (25.0)
WOMAC total score 65 36 (55.4) 3 (4.6) 7 (10.8) 5 (7.7) 14 (21.5)
WOMAC function subscale 93 59 (63.4) 4 (4.3) 8 (8.6) 8 (8.6) 14 (15.1)
WOMAC stiffness subscale 82 51 (62.2) 2 (2.4) 7 (8.5) 8 (9.8) 14 (17.1)
30 % pain reduction responder 14 4 (28.6) 1 (7.1) 2 (14.3) 4 (28.6) 3 (21.4)
Patient responder 61 44 (72.1) 1 (1.6) 7 (11.5) 4 (6.6) 5 (8.2)
Clinician responder 35 26 (74.3) 0 (0) 5 (14.3) 3 (8.6) 1 (2.9)
OMERACTeOARSI responder 18 12 (66.7) 2 (11.1) 4 (22.2) 0 (0) 0 (0)
* Values for numbers of active treatment groups and percentages, which may not sum to 100% due to rounding.
y Individually or in combination.
z Includes tramadol or tramadol in combination with acetaminophen.
x Item one of the WOMAC pain subscale.
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different active treatment arms had sufﬁcient data to compute the
treatment effect for at least one measure. The majority of these
RCTs examined only knee OA (66%), followed by the combination of
knee OA and hip OA (30%), and hip OA only (5%). The categories of
recommended treatments examined in these trials were predom-
inantly non-steroidal anti-inﬂammatory drugs (NSAIDs) followed
by opioid analgesics, glucosamine and/or chondroitin, and acet-
aminophen/paracetamol (Table I).
Pain
For the pain-related outcome measures presented in Table II,
estimated treatment effects ranged from 7.6 to 9.5 (all outcomes
converted to a 0e100 scale) and estimated SESs ranged from 0.21 to
0.45. Treatment effect estimates were generally comparable
between typically single-item NRS or VAS pain intensity measures
and the WOMAC ﬁve-item pain subscale. The SES for the WOMAC
pain subscale (0.45) was appreciably higher than the SES for the
measures of spontaneous pain (0.27), but this difference was not
statistically signiﬁcant (p¼ 0.09; Table V) and was based on data
from 32 studies (13 for spontaneous pain, 19 for the WOMAC pain
scale).Table II
Treatment vs placebo group differences and SESs for pain-related outcome measures for
Measure Pain Pain (with ac
N* Mean 95% CIy N Mean 9
Treatment vs placebo group difference
All scales, random effects modelz 29 9.4 7.2, 11.6 11 7.7 3
Scales 10 categories, random effects modelz 27 8.7 6.9, 10.5 10 7.6 3
All scales, unweighted, all armsx 67 11.4 28 10.3
SES
All scales, random effects modelz 13 0.27 0.11, 0.43 7 0.22 0
Scales 10 categories, random effects modelz 13 0.27 0.11, 0.43 6 0.21 0
All scales, unweighted, all armsx 19 0.29 8 0.25
* Number of active treatment arms (one value per treatment).
y CI¼ conﬁdence interval.
z Estimate from random effects model with one randomly selected treatment include
x Conﬁdence intervals are not provided because their calculation would assume the sta
case due to the inclusion of multiple treatment comparisons with the same placebo groResponder analyses based on a reduction in pain of 30% from
baseline to endpoint showed a treatment effect of 16.1 (i.e., the
difference in percentages of responders between the active treat-
ment and placebo arms) for scales with 10 categories (there were
inadequate data for scales with <10 categories). These responder
analyses were based on a variety of different pain outcome
measures, including spontaneous pain, pain with activity, WOMAC
pain subscale scores, and pain walking (item one of the WOMAC
pain subscale).
Patient and clinician global measures and response to treatment
measures
Most trials in the database used patient and clinician global
measures of disease activity to assess response, typically as
secondary endpoints. The range in estimates for patient and clini-
cian global measures was 5.6e13.2 for treatment effects and
0.20e0.68 for SESs (Table III). The estimates of treatment effect
and SES were signiﬁcantly higher for patient global measures
compared with clinician global measures using scales with 10
categories, but the differences were not signiﬁcant for scales with
<10 categories (Table V). For patient measures of response to
treatment, ﬁve trials provided the basis for estimates of treatmentrecommended treatments
tivity) WOMAC pain subscale WOMAC pain walking 30% pain reduction
(% patients)
5% CI N Mean 95% CI N Mean 95% CI N Mean 95% CI
.6, 11.8 36 8.4 6.3, 10.5 6 9.5 6.7, 12.3 6 16.1 4.4, 27.8
.1, 12.1 36 8.4 6.3, 10.5 6 16.1 4.4, 27.8
81 8.9 21 9.9 11 15.7
.08, 0.36 26 0.40 0.27, 0.53 6 0.39 0.25, 0.52
.05, 0.37 26 0.40 0.27, 0.53
44 0.43 9 0.45
d per trial.
tistical independence of the results from all of the trials, which does not hold in this
up in some of the trials.
Table III
Treatment vs placebo group differences and SESs for patient- and clinician-rated outcome measures for recommended treatments
Measure Patient global Patient
treatment
response
Patient
responder
(% patients)
Clinician global Clinician
treatment
response
Clinician
responder
(% patients)
N* Mean 95% CIy N Mean 95% CI N Mean 95% CI N Mean 95% CI N Mean 95% CI N Mean 95% CI
Treatment vs placebo group difference
All scales, random
effects modelz
26 10.7 8.5, 12.9 5 17.1 13.2, 21.0 41 23.1 19.8, 26.4 18 8.6 6.6, 10.6 28 24.5 19.6, 29.4
Scales 10 categories,
random effects modelz
20 10.1 7.5, 12.7 7 5.6 3.4, 7.8
Scales < 10 categories,
random effects modelz
6 13.2 10.0, 16.4 5 17.1 13.2, 21.0 41 23.1 19.8, 26.4 11 10.9 8.8, 13.0 28 24.5 19.6, 29.4
All scales, unweighted,
all armsx
61 12.0 20 15.5 56 23.1 48 10.9 11 18.4 34 24.5
SES
All scales, random
effects modelz
19 0.38 0.27, 0.49 5 0.68 0.48, 0.88 15 0.34 0.24, 0.45
Scales 10 categories,
random effects modelz
15 0.38 0.24, 0.52 6 0.20 0.14, 0.26
Scales < 10 categories,
random effects modelz
5 0.68 0.48, 0.88 9 0.46 0.33, 0.59
All scales, unweighted,
all armsx
44 0.44 9 0.66 33 0.40 7 0.74
* Number of active treatment arms (one value per treatment).
y CI¼ conﬁdence interval.
z Estimate from random effects model with one randomly selected treatment included per trial.
x Conﬁdence intervals are not provided because their calculation would assume the statistical independence of the results from all of the trials, which does not hold in this
case due to the inclusion of multiple treatment comparisons with the same placebo group in some of the trials.
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gories. There were inadequate data to compute these estimates
for scales with 10 categories and the clinician measures of
response to treatment.
All of the patient and clinician responder outcomes were based
on scales with <10 categories. Treatment effects (i.e., the difference
in percentages of responders between the active treatment and
placebo arms) for patient (23.1) and clinician (24.5) responder
outcomes were very similar.
Function and composite measures
For the function, stiffness, and composite outcome measures,
the estimates of treatment effects (5.3e8.3) and SESs
(0.25e0.37) were relatively modest (Table IV), and the SESs for
the Lequesne index and WOMAC total score were similarTable IV
Treatment vs placebo group differences and SESs for function, stiffness, and composite o
Measure WOMAC function
subscale
Lequesne
algofunctiona
N* Mean 95% CIy N Mean 9
Treatment vs placebo group difference
All scales, random effects modelz 36 6.8 5.5, 8.2 14 5.3 3
Scales 10 categories, random effects modelz 36 6.8 5.5, 8.2 14 5.3 3
Scales < 10 categories, random effects modelz
All scales, unweighted, all armsx 79 7.6 24 5.7
SES
All scales, random effects modelz 26 0.33 0.25, 0.41 6 0.34 0
Scales 10 categories, random effects modelz 26 0.33 0.25, 0.41 6 0.34 0
Scales < 10 categories, random effects modelz
All scales, unweighted, all armsx 44 0.35 8 0.37
* Number of active treatment arms (one value per treatment).
y CI¼ conﬁdence interval.
z Estimate from random effects model with one randomly selected treatment include
x Conﬁdence intervals are not provided because their calculation would assume the sta
case due to the inclusion of multiple treatment comparisons with the same placebo gro(Table V). There were 11 studies with a total of 18 different active
treatment arms that provided data for the OMERACTeOARSI
responder criteria. The estimated treatment effect (i.e., the
difference in percentages of responders between the active
treatment and placebo arms) was 12.7, which was somewhat
lower than the treatment effects for the responder analyses of
30% pain reduction presented in Table II and the responder
outcomes based on patient and clinician measures presented in
Table III.
Discussion
We conducted a meta-analysis of the responsiveness of the
outcome measures that are used most frequently in RCTs of OA.
These measures include patient-reported assessments of pain,
physical function, stiffness, global status, treatment response, andutcome measures for recommended treatments
l index
WOMAC stiffness
subscale
WOMAC total score OMERACTeOARSI
responder
(% patients)
5% CI N Mean 95% CI N Mean 95% CI N Mean 95% CI
.5, 7.1 33 7.4 5.7, 9.2 24 5.5 4.4, 6.6 11 12.7 7.8, 17.6
.5, 7.1 22 8.3 5.9, 10.7 24 5.5 4.4, 6.6
11 5.9 4.1, 7.8
68 8.2 55 6.9 18 13.2
.20, 0.48 25 0.32 0.23, 0.41 15 0.30 0.24, 0.36
.20, 0.48 16 0.37 0.25, 0.49 15 0.30 0.24, 0.36
9 0.25 0.17, 0.33
43 0.34 27 0.34
d per trial.
tistical independence of the results from all of the trials, which does not hold in this
up in some of the trials.
Table V
Comparison of pain, global, and composite outcome measures for recommended treatments
Measure Pain WOMAC
pain
subscale
Patient
global
Clinician
global
WOMAC
total
score
Lequesne
N* Mean N Mean Difference
(95% CIy)
Pz N Mean N Mean Difference
(95% CI)
P N Mean N Mean Difference
(95% CI)
P
Treatment vs placebo group difference
All scales, random
effects modelx
29 9.6 26 9.4 0.2 (3.2, 3.6) .90 11 11.8 18 8.7 3.1 (0.5, 6.7) .09 22 5.7 14 5.2 0.6 (1.5, 2.6) .40
Scales 10 categories,
random effects modelx
27 9.0 27 9.4 0.3 (2.9, 3.6) .83 13 12.3 7 5.8 6.5 (2.0, 11.1) .01 22 5.7 14 5.2 0.6 (1.5, 2.6) .40
Scales <10 categories,
random effects modelx
6 13.2 8 10.5 2.7 (1.3, 6.7) .19
SES
All scales, random
effects modelx
13 0.27 19 0.45 0.19
(0.03, 0.40)
.09 7 0.42 15 0.34 0.07
(0.12, 0.26)
.55 14 0.31 6 0.34 0.03
(0.11, 0.17)
.65
Scales 10 categories,
random effects modelx
13 0.27 19 0.45 0.19
(0.03, 0.40)
.09 9 0.50 6 0.20 0.30
(0.07, 0.43)
.01 14 0.31 6 0.34 0.03
(0.11, 0.17)
.65
Scales <10 categories,
random effects modelx
4 0.41 8 0.47 .06
(0.15, 0.27)
.56
* Number of active treatment arms (one value per treatment).
y CI¼ conﬁdence interval.
z P value for difference between measures.
x All values estimated from random effects model with one randomly selected treatment included per trial. When both measures were included in the same trial, the
measure with the highest N in each of the three analyses (all scales, scales with 10 categories, scales with <10 categories) was deleted from that trial.
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various responder outcomes. For patient-reported pain outcomes,
there were generally comparable treatment effect estimates for the
different measures, including single VAS or NRS ratings of overall
pain or pain with activity (e.g., pain walking) and the multi-item
WOMAC pain subscale. However, the mean SES for pain rated on
single scales with 10 response categories was considerably lower
than the mean SES for the WOMAC pain subscale (0.27 vs 0.45;
p¼ .09, 95% conﬁdence interval (CI) for difference¼0.03, 0.40).
Although this difference was not statistically signiﬁcant and was
based on a total of only 32 trials, SES differences of this magnitude
would have important implications with respect to sample size,
with considerably fewer patients being required for adequate
statistical power if the WOMAC pain subscale were to be used
rather than a single pain rating. However, these results need to be
interpreted with caution because it is possible that confounding
factors d that is, systematic differences between trials using
a single pain rating and those using the WOMAC pain subscale d
may have inﬂuenced these results.
The conclusion that different patient-reportedoutcomemeasures
of pain severity may have generally comparable responsiveness to
treatment is consistent with the results of data analyses from single
clinical trials29,30; for example, the difference between improvement
in pain on the WOMAC pain subscale and on a VAS following knee
lavage was not signiﬁcant29. In research comparing VAS and Likert
versions of theWOMAC31,32, and in other studies of OA pain assessed
using VAS and Likert scales33,34, generally comparable responsive-
ness to change of these different rating scales has been found.
Different pain measures and scales may not always be interchange-
able35, however, and there are circumstances in which one type of
assessmentmight bepreferred14. Althoughwe foundnon-signiﬁcant
differences in favor of theWOMAC pain subscale, which will need to
be examined in future research, considered together with the results
of previous research, our analyses suggest that different measures of
pain in patients with OA may have generally comparable ability to
identify efﬁcacious treatments.
The analyses of global outcome measures showed larger treat-
ment effects and a trend toward larger SESs for patient-reported vs
clinician-rated measures (but only for measures with10 responsecategories). This result may not be surprising. It is likely that global
assessments made by clinicians are based, in large part, on what
patients report to them, and improvement in pain, which is
a subjective experience, appears to account for a major portion of
the variation in patient global assessments of outcome and treat-
ment satisfaction36. These considerations5,13,14 and our data suggest
that patient global measures are likely to provide more valid and
responsive outcomes in analgesic RCTs than clinician global
measures in most circumstances.
Treatment effects and SESs were generally lower or comparable
for the function and composite measures compared with the pain,
global, and responder outcomes, which is consistent with the
results of other studies in patients with OA29,34,37. Treatment effects
for the OMERACTeOARSI responder criteria were somewhat lower
than for the other responder outcomes, which were typically based
on single-item pain or global ratings. Multidimensional measures
of outcome d such as the WOMAC, Lequesne index, and OMER-
ACTeOARSI responder criteria d may provide a more compre-
hensive assessment of the patient’s overall response to treatment,
but it is not clear why this might lead to lower responsiveness to
treatment effects than found with unidimensional measures. One
possibility is that existingmedications for pain in OA have analgesic
effects that are generally modest and do not reduce pain to low
enough levels for improvements in function to become apparent. In
addition, some of these treatments may not have meaningful
beneﬁts on the additional outcome dimensions included in the
composite outcome measures. Of course, these observed differ-
ences also may be due to chance or confounding.
Our results are based on a meta-analysis of clinical trials that
were conducted using different research designs, treatments, and
outcomes, an approach that has also been used recently to evaluate
the “discriminating power” of outcomemeasures in clinical trials of
ﬁbromyalgia38. A different approach to examining the assay
sensitivity of outcome measures involves evaluating treatment
effects and SESs in a single clinical trial in which each patient
completes all of the measures and patient-level data, rather than
the group means used in our analyses, provide the basis for
comparing measures29,39e41. However, the generalizability of such
results is potentially limited by speciﬁc features of the clinical trial,
R.H. Dworkin et al. / Osteoarthritis and Cartilage 19 (2011) 483e492 489including patient demographic and clinical characteristics and
study methodology (e.g., trial duration42) as well as the speciﬁc
treatment examined. The present meta-analysis provides
a comparative evaluation of the responsiveness of outcome
measures across a broad range of patients, clinical trial character-
istics, and treatments.
It is important to emphasize that the heterogeneity of the
sample of trials we examined is also a limitation of our analyses.
The treatment effects and SESs for the different outcome
measures could reﬂect not only potential differences among the
measures in responsiveness to treatment but also differences
among trials in methods, treatment efﬁcacy and safety, impu-
tation of missing data, study duration, and random varia-
tion19,43,44. For example, we did not adjust for whether trials
used a ﬂare design, which has recently been shown to accen-
tuate the treatment effects of NSAIDs21, perhaps by enriching for
those patients who are most likely to respond to treatment;
differences in the use of this design across the outcome
measures we examined could have inﬂuenced our results. In
addition, the frequency with which the outcome measures we
examined were administered varied greatly among trials; for
example, some RCTs conducted pain ratings on a daily basis and
examined the means of such multiple ratings, whereas others
only captured pain weekly or monthly and examined single
ratings. Measures that use multiple assessments d on different
occasions or within a single measure, for example, the ﬁve items
of the WOMAC pain subscaled generally have greater reliability,
which might be associated with increased responsiveness to
treatment effects.
There are other important limitations of our analyses. We
considered glucosamine and chondroitin to be efﬁcacious treat-
ments, although recent evidence suggests that they might not be45
(this conclusion, however, has been disputed46). In addition, it is
widely recognized that negative trials are less likely to be
published, and our analyses were limited to published and publicly-
available RCTs; estimates of treatment effects based on the
published literature are therefore likely to be higher than if all RCTs
could be examined47,48 and this could have inﬂuenced our results.
Our analyses were also limited to trials published or reported in
English, and it is therefore possible that the inclusion of RCT results
that are only available in other languages might have altered our
conclusions. Finally, our results must also be viewed with sample
size limitations in mind. Although the number of studies available
for computing estimates of treatment effects and SESs was limited
for some measures, all of the mean estimates we have presented
are based on the results of at least ﬁve trials25 and the treatment
effect estimates represent total numbers of patients ranging from
1,296 (clinician treatment response) to 13,486 (WOMAC function
subscale). Nevertheless, it is important to recognize that there were
a substantial number of trials in the database that did not report
information from which an appropriate measure of variability
could be determined for calculating treatment effect and SES esti-
mates. This made the sample sizes for our meta-analyses consid-
erably smaller than if there had been more complete reporting of
the results of the clinical trials in the database. Improvements in the
quality of the reporting of clinical trial results are needed to
facilitate meta-analyses such as those performed here.
The assay sensitivity of an outcome measure is a function of
the separation between measured improvement in the active
treatment group and in the placebo group. It is widely appreci-
ated that substantial improvements in pain occur in the placebo
groups of OA trials20,49, and “excessive” placebo group improve-
ment for an outcome measure could compromise its responsive-
ness. Beneﬁt in placebo groups can be due to multiple factors
alone and in combination, including placebo effects, naturalhistory, regression to the mean, and various subject, study site,
and research design factors. In future research, it would be
worthwhile to examine whether different types of outcome
measures vary in the extent to which improvement is demon-
strated with placebo treatment. Identifying speciﬁc outcome
measures that are less responsive to placebo treatment than are
other measures (while showing comparable responsiveness as the
other measures to active treatments) has the potential to show
greater treatment effects and thereby improve the assay sensi-
tivity of analgesic trials19.
There is little question that our analyses will need to be
updated in several years. One important reason for this is that
new outcome measures and new approaches to evaluating
outcome in RCTs of pain in OA are being developed. For example,
recent research has examined electronic pain diaries of various
types50, including mobile phones51, and such methods may
increase the convenience of collecting more frequent, and
therefore, more reliable pain ratings (although there is little
evidence to date that these measures show greater responsive-
ness to treatment). There has also been increasing attention to
evaluating the clinical importance of outcome measures14,52,
including the identiﬁcation of low or acceptable levels of
symptoms53,54. In addition, the importance of considering the
patient’s perspective has been emphasized15,55, and initial
attempts have been made to develop patient-centered outcome
measures that assess the speciﬁc treatment goals of individual
patients56e58. These efforts may lead to the identiﬁcation of
outcome measures with greater reliability, validity, and respon-
siveness, which could increase the assay sensitivity of clinical
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Appendix I
Treatment vs. placebo group differences, SESS, and study outcomes for osteoarthritis outcome measures for all treatments and arms
Pain Pain (with
activity)
WOMAC pain
subscale
WOMAC pain
walking
30% pain
reduction
(% patients)
N* Meany N Mean N Mean N Mean N Mean
Treatment vs placebo group difference, unweighted 83 10.9 30 10.7 99 8.6 21 9.8 14 14.8
SES, unweighted 22 0.32 8 0.25 48 0.42 9 0.44
% positivez 101 75.3 38 86.8 118 76.3 21 90.5 15 66.7
Patient global Patient
treatment
response
Patient
responder
(% patients)
Clinician
global
Clinician
treatment
response
Clinician
responder
(% patients)
N Mean N Mean N Mean N Mean N Mean N Mean
Treatment vs placebo group difference, unweighted 66 11.5 20 15.5 61 23.7 50 10.6 11 18.4 35 24.3
SES, unweighted 34 0.39 9 0.66 29 0.37 5 0.74
% positivez 93 74.1 26 80.1 63 84.1 68 80.9 14 71.4 34 88.2
WOMAC
function
subscale
Lequesne
algofunctional
index
WOMAC
stiffness
subscale
WOMAC
total score
OMERACTe
OARSI
responder
criteria
(% patients)
N Mean N Mean N Mean N Mean N Mean
Treatment vs placebo group difference, unweighted 93 7.6 32 5.8 82 7.8 65 7.8 18 13.2
SES, unweighted 47 0.35 10 0.39 46 0.33 29 0.34
% positivez 120 70.0 40 62.5 104 65.4 78 71.8 23 82.6
* Number of active treatment arms (one value per treatment).
y Conﬁdence intervals are not provided because their calculation would assume the statistical independence of the results from all of the trials, which does not hold in this
case due to the inclusion of multiple treatment comparisons with the same placebo group in some of the trials.
z For “% positive,” the outcome for each treatment arm was categorized as positive if the comparison with placebo for a given measure yielded a statistically signiﬁcant
(p 0.05) treatment effect, and the percentage of positive outcomes was calculated by dividing the number of treatment arms (one for each active treatment per trial) with
a positive outcome by the total number of treatment arms. The outcome for multiple arms of the same treatment in a trial was categorized as positive if at least one of the arms
was positive. The number of treatment arms for this variable can be higher than for the unweighted treatment effect because some studies provided values for outcome but
insufﬁcient information to compute treatment effects.
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